SiTime stock price target raised to $324 from $240 at Stifel

Investing.com - Stifel raised its price target on SiTime Corporation (NASDAQ:SITM) to $324.00 from $240.00 on Thursday, while maintaining a Buy rating on the precision timing solutions provider. The company has demonstrated strong momentum, with shares surging over 200% in the past year despite recent market volatility.

The price target increase follows SiTime’s September 17 launch of its Titan Platform, which marks the company’s entry into the $4 billion resonator market and positions it as the industry’s only provider offering a complete suite of precision timing solutions.

The Titan Platform immediately expands SiTime’s serviceable addressable market (SAM) by $400 million, representing approximately 10% of the total addressable market (TAM), with potential to reach $1 billion by 2028 through additional product variants and market growth.

Stifel believes this new resonator platform extends SiTime’s technology leadership and further disrupts the legacy $10 billion-plus quartz-based timing market, while enabling customers to deliver enhanced form, function, and features across growth applications including wearables, medical devices, smart home, and industrial/IoT sectors.

The new price target of $324 represents 19.9x EV/CY26E sales, reflecting Stifel’s confidence in SiTime’s expanded market opportunity.

In other recent news, Neuronetics Inc. reported its financial results for the second quarter of 2025, revealing a revenue of $38.1 million, which exceeded both the consensus forecast of $36.8 million and Canaccord Genuity’s estimate of $37.2 million. Despite this revenue beat, the company posted a larger-than-expected loss per share of -$0.15, missing the forecast of -$0.08. This earnings miss has raised investor concerns. Meanwhile, Canaccord Genuity lowered its price target for Neuronetics from $8.00 to $7.00, although it maintained a Buy rating on the stock. The adjustment was made following the company’s earnings report, with particular attention to margin concerns. Additionally, over 5 million New York Medicaid members will gain access to Neuronetics’ Transcranial Magnetic Stimulation (TMS) therapy for major depressive disorder starting this fall. Coverage will begin on October 1 for fee-for-service Medicaid members and on November 1 for those in Medicaid Managed Care Plans. These developments highlight significant changes and challenges for Neuronetics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.